TCR2 THERAPEUTICS INC. Quarterly Debt-to-equity in % from Q3 2019 to Q1 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Tcr2 Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q1 2023.
  • Tcr2 Therapeutics Inc. Debt-to-equity for the quarter ending March 31, 2023 was 41 %, a 154% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2023 41 +24.9 +154% Mar 31, 2023
Q4 2022 35.5 +22.2 +168% Dec 31, 2022
Q3 2022 27.7 +16.5 +149% Sep 30, 2022
Q2 2022 21.7 +12.8 +144% Jun 30, 2022
Q1 2022 16.2 +8.81 +120% Mar 31, 2022
Q4 2021 13.3 +9.13 +221% Dec 31, 2021
Q3 2021 11.1 +6.75 +155% Sep 30, 2021
Q2 2021 8.89 +3.97 +80.6% Jun 30, 2021
Q1 2021 7.36 +2.7 +58% Mar 31, 2021
Q4 2020 4.14 -0.09 -2.13% Dec 31, 2020
Q3 2020 4.37 -1.65 -27.4% Sep 30, 2020
Q2 2020 4.92 Jun 30, 2020
Q1 2020 4.66 Mar 31, 2020
Q4 2019 4.23 Dec 31, 2019
Q3 2019 6.02 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.